National Changhua University of Education Institutional Repository : Item 987654321/13220
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 6507/11669
造訪人次 : 30247493      線上人數 : 465
RC Version 3.2 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 進階搜尋

請使用永久網址來引用或連結此文件: http://ir.ncue.edu.tw/ir/handle/987654321/13220

題名: Synergistic Effect of Combined Etodolac Plus 5-Fluorouracil in Human Hepatoma Therapy--an In vitro Evaluation by Cell Lines HepG2, HA22T and KELFIB
作者: Hsieh, Chiu-Lan;Peng, Chiung-Huei;Hsiao, George T.;Wang, Hui-Er;Ko, Wan-Shen;Peng , Robert Y.
貢獻者: 生物技術研究所
關鍵詞: Hepatoma;COX-2 inhibitor etodolac;5-FU;Chemotherapy
日期: 2007
上傳時間: 2012-08-07T06:57:23Z
出版者: Medwell
摘要: Hepatocellular Cancer Cell (HCC) lines HepG2, HA22T and KEL FIB were used to test the therapeutic effect of different combined protocols for etodolac plus 5-FU: 1). the selective COX 2 inhibitor etodolac alone at 0.0~0.16 �g �L 1; 2). 5-FU alone at 0.0~1.25 �g mL 1; 3). etodolac (0.31 �g �L 1) plus 5-FU (1.25 �g mL 1) in a simultaneous-, or an alternative sequential protocol. Cell viability was measured using MTT assay and flow cytometric analysis. An inverse dose dependent survival rate was observed for both drugs, while the apoptotic data of the three HCC cell lines have favored the simultaneous administration of etodolac plus 5-FU, which revealed to be more effective than administering etodolac or 5-FU alone. We conclude that in view of the therapeutic efficacy with a minimized cytotoxicity, a simultaneous administration of etodolac plus 5-FU, each at much more reduced dosages than usually prescribed alone, could be strongly recommended for treatment of HCC.
關聯: Research Journal of Biological Sciences, 2(3): 268-279
顯示於類別:[生物技術研究所] 期刊論文

文件中的檔案:

檔案 大小格式瀏覽次數
index.html0KbHTML638檢視/開啟


在NCUEIR中所有的資料項目都受到原著作權保護.

 

DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋